GMP Manufacturing for AAV Therapeutics | AskBio

AskBio is a clinical-stage gene therapy company dedicated to developing AAV gene therapies for genetic and complex disorders. The company is wholly owned and independently operated as a subsidiary of Bayer AG. AskBio's platform focuses on advancing genetic technology and AAV gene therapy to address life-altering diseases, with a commitment to lowering production costs and increasing treatment supply for patients. The company's clinical pipeline is informed by direct engagement with patients, families, care teams, and disease-advocacy organizations. AskBio has demonstrated clinical progress, including FDA Fast Track and Orphan Drug designations for its investigational programs, and is actively enrolling participants in Phase 1/Phase 2 clinical trials for rare genetic disorders such as late-onset Pompe disease.